Geoff McDonough, Generation Bio president and CEO

Mod­er­na part­ners on non-vi­ral gene ther­a­py with Gen­er­a­tion Bio af­ter swing­ing gene edit­ing deals

Mod­er­na has inked a five-year part­ner­ship with gene ther­a­py biotech Gen­er­a­tion Bio, it an­nounced Thurs­day morn­ing, wad­ing deep­er in­to the ge­net­ic med­i­cines space as it nav­i­gates be­yond its vac­cine work.

Mod­er­na will pay Gen­er­a­tion Bio $40 mil­lion up­front and in­vest an­oth­er $36 mil­lion in­to the gene ther­a­py biotech. In ex­change, Mod­er­na can li­cense Gen­er­a­tion Bio’s non-vi­ral gene ther­a­py plat­forms for two im­mune cell pro­grams and two liv­er pro­grams, with an op­tion for a fifth pro­gram. Mod­er­na will fund all the re­search work un­der the part­ner­ship, and could be on the hook for mile­stone, fee and roy­al­ty pay­ments to­tal­ing up to $1.8 bil­lion, a com­pa­ny spokesper­son tells End­points News.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters